ArticleACS medicinal chemistry letters2018
Design, Synthesis, and Characterization of Novel Small Molecules as Broad Range Antischistosomal Agents.
Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Antischistosomal activity of imidazolidine-2,4-dione derivatives.Antimicrobial agents and chemotherapy · 2026Article
- Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-ResistantPharmaceutics · 2025Review
- Schistosomiasis.Advances in experimental medicine and biology · 2024Review
- Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis.PLoS pathogens · 2023Article
- Schistosome Sulfotransferases: Mode of Action, Expression and Localization.Pharmaceutics · 2022Article
- An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans.PLoS neglected tropical diseases · 2020Article
- Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?International journal for parasitology. Drugs and drug resistance · 2020Article
- Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?RSC medicinal chemistry · 2020Review
- Molecular basis for hycanthone drug action in schistosome parasites.Molecular and biochemical parasitology · 2020Article
- Non-sedating benzodiazepines cause paralysis and tissue damage in the parasitic blood fluke Schistosoma mansoni.PLoS neglected tropical diseases · 2019Article
- Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment.PLoS pathogens · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis is a major human parasitic disease afflicting more than 250 million people, historically treated with chemotherapies praziquantel or oxamniquine. Since oxamniquine is species-specific, killing
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.